The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).

Sukul, Devraj

The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). [electronic resource] - Journal of interventional cardiology Aug 2017 - 291-300 p. digital

Publication Type: Comparative Study; Journal Article

1540-8183

10.1111/joic.12388 doi


Abciximab
Aged
Antibodies, Monoclonal--therapeutic use
Blue Cross Blue Shield Insurance Plans
Contraindications, Drug
Eptifibatide
Female
Heparin--therapeutic use
Humans
Immunoglobulin Fab Fragments--therapeutic use
Male
Michigan
Middle Aged
Myocardial Infarction--therapy
Peptides--therapeutic use
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors--therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors
Postoperative Complications--epidemiology
Renal Dialysis
Retrospective Studies
Treatment Outcome